Clinical laboratory singleplex testing — the enzyme-linked immunosorbent assay (ELISA) and chemiluminescent immunoassay (CLIA) for individual analyte quantification in patient samples representing the regulatory-validated, reimbursement-established diagnostic foundation — creates the most commercially dynamic market segment, with the Singleplex Immunoassay Market reflecting clinical diagnostics as the validation-driven commercial driver.

Thyroid function testing volume — the TSH, free T4, free T3, and anti-TPO antibody testing representing 200M+ annual tests globally and the largest singleplex immunoassay category creating the high-volume reference. Roche, Abbott, and Siemens Healthineers dominating automated CLIA platforms with 10-15 minute TSH turnaround, with clinical guidelines requiring TSH-first screening and reflex free T4 confirmation maintaining the singleplex sequential logic demonstrates the clinical-protocol commercial impact.

Infectious disease serology — the HIV Ag/Ab combo, hepatitis B surface antigen, HCV antibody, and syphilis TP-PA singleplex tests for blood bank screening, prenatal testing, and diagnostic confirmation creating the infectious disease segment. FDA-approved singleplex assays required for blood donor screening with 99.9%+ sensitivity, with multiplex screening (HIV/HCV/HBV combo) followed by singleplex confirmation maintaining the two-tier algorithm.

Cardiac biomarker standardization — the hs-cTnI, hs-cTnT, and NT-proBNP singleplex assays with International Federation of Clinical Chemistry (IFCC) standardization creating the inter-laboratory harmonization segment. 99th percentile URL (upper reference limit) establishment for each assay platform requiring singleplex specificity, with the 2022 Universal Definition of MI mandarding sex-specific 99th percentiles and 20% delta change criteria.

Do you think multiplex protein arrays will eventually replace singleplex for routine clinical chemistry, or will regulatory validation requirements, reimbursement codes, and clinical habit maintain singleplex dominance for years?

What are the specific clinical singleplex platforms, their throughputs, and test menus? Major platforms: Roche cobas e: e411; e601; e801; CLIA; ECL; 90-300 tests/hour; menu: 100+; immunoassays; Abbott Alinity i: CLIA; 200 tests/hour; menu: 80+; Siemens Atellica IM: CLIA; 200 tests/hour; menu: 90+; Beckman Coulter Access 2: CLIA; 100 tests/hour; menu: 70+; Ortho Vitros: ECi; 150 tests/hour; menu: 60+; Tosoh AIA: G8; 80 tests/hour; menu: 50+; Menarini (Shenzhen): CLIA; 100 tests/hour; menu: 40+; emerging; Test categories: thyroid: TSH; FT4; FT3; TPOAb; TGAb; TG; largest; volume; cardiac: hs-cTnI; hs-cTnT; NT-proBNP; CK-MB; MYO; D-dimer; infectious: HIV; Ag/Ab; HBsAg; anti-HCV; syphilis; TB; fertility: FSH; LH; E2; P; PRL; hCG; tumor: AFP; CEA; CA125; CA19-9; PSA; CA15-3; anemia: B12; folate; ferritin; iron; TIBC; bone: PTH; 25-OH-D; 1,25-OH-D; OC; BALP; Pricing: reagent cost: $1-5; per; test; high; volume; $5-15; per; test; low; volume; specialty; instrument: $50,000-300,000; depending; throughput; menu; service: $10,000-50,000; annually; maintenance; contract; total: $3-8; per; test; fully; loaded; reimbursement: $10-30; per; test; Medicare; commercial; margin: 30-50%; laboratory.

How does regulatory validation (FDA, CE-IVD, IVD-R) govern singleplex clinical immunoassay approval and market access? FDA: 510(k): most; singleplex; CLIA; moderate; complexity; PMA: HIV; blood; screening; high; complexity; de novo: novel; biomarkers; new; pathways; CLIA complexity: waived: POC; limited; moderate: laboratory; high: reference; complex; validation: analytical: precision; accuracy; linearity; range; sensitivity; specificity; clinical: reference; interval; diagnostic; sensitivity; specificity; PPV; NPV; clinical; utility; studies; CE-IVD (EU): IVDR: 2017/746; Class B; C; D; singleplex; mostly; B; C; notified; body; review; technical; documentation; performance; evaluation; post-market; surveillance; IVD-R: China: NMPA; Class II; III; clinical; trial; required; for; novel; Japan: PMDA; similar; to; FDA; 510(k); pathway; Challenges: validation cost: $500,000-2,000,000; per; assay; 2-3 years; timeline; reference: standardization; harmonization; IFCC; commutable; materials; lot-to-lot: consistency; bridging; studies; quality; control; Future: harmonization: global; standards; mutual; recognition; AI: automated; validation; quality; control; prediction; point-of-care: waived; singleplex; expansion; home; testing.